TEVA PHARMACEUTICAL INDUSTRIES LTD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

Filed by the Registrant

☒

Filed by a Party other than the Registrant

☐

Check the appropriate box:

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

Notice of 2026 Annual

Meeting of Shareholders

The 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Teva Pharmaceutical Industries Limited (“we,” “us,” “our,” “Teva” or the “Company”) will be conducted in a virtual format through an online meeting platform. For further information, see “Questions and Answers” below. In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2025. Teva encourages all of its shareholders to review its annual report on Form 10-K for the year ended December 31, 2025 (“Annual Report”). Only holders of ordinary shares (or American Depositary Shares representing such ordinary shares) of record at the close of business on April 6, 2026, will be entitled to vote at the Annual Meeting. Pursuant to the Israeli Companies Law and our Articles of Association, two holders of ordinary shares who are present at the Annual Meeting, in person or by proxy or represented by their authorized persons, and who hold in the aggregate twenty-five percent or more of such ordinary shares, shall constitute a legal quorum. Should no legal quorum be present one-half hour after the scheduled time, the Annual Meeting shall be adjourned to one week from that day, at the same time and format. By Order of the Board of Directors, Dov Bergwerk Senior Vice President, Company Secretary March 31, 2026 Agenda 1. Director Election 2. Advisory Vote on Compensation of Named Executive Officers 3. Appointment of Independent Registered Public Accounting Firm

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be Held on May 28, 2026

The accompanying Proxy Statement and our Annual Report are available at www.tevapharm.com/2026proxymaterials. We expect the proxy materials to be mailed and/or made available on or before April 9, 2026.

Dear Valued Shareholder,

Teva delivered another milestone year in 2025. We advanced our Pivot to Growth strategy and continued to transform into a leading innovative biopharmaceutical company. We further strengthened our foundation forlong-term, sustainable value creation. Your Board remains committed to responsible governance and rigorous strategic oversight, as Teva continues building durable shareholder value and improving health outcomes for patients around the world.

Executing Our Pivot to Growth Strategy

In 2025, your Board of Directors continued to work closely with management to advance Teva’s growth strategy. Together, we delivered meaningful progress across all four pillars of our Pivot to Growth strategy:

Delivering on our growth engines: Our innovative medicines portfolio continued to demonstrate strong momentum. AUSTEDO® for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia, maintained robust double-digit growth as global demand expanded. UZEDY® for the treatment of schizophrenia in adults, gained further traction in the U.S., and the FDA expanded UZEDY’s indication approval for Bipolar 1 disorder in adults. AJOVY® injection for the preventive treatment of migraine in

adults and children and adolescent patients, continued to show meaningful performance, with further expansion in key markets. Across the portfolio, we strengthened commercial execution and expanded patient access as we continued evolving toward a more innovation-driven Teva.

Stepping-up innovation: Our R&D pipeline advanced significantly, with continued progress inlate-stage assets and multiple key readouts expected in 2026–2027. We continued to advance our olanzapine LAI program, incorporating learnings from prior clinical phases and preparing for pivotal next steps. Following positive Phase 2b results on duvakitug, ouranti-TL1A candidate, we initiated its Phase 3 clinical

Teva Pharmaceutical Industries Ltd.2026 Proxy Statement trial and entered into an additional strategic funding partnership in early 2026. Our broader pipeline, including both biologics and innovative programs, benefited from accelerated development timelines supported by external funding partnerships and the expanded use of AI-enabled modeling and trial analytics.

Sustaining our generics medicines powerhouse: We continued strengthening Teva’s position as a global leader in generics by increasing our focus onhigh-value, complex products and biosimilars. We launched several important generics across key therapeutic areas and advanced multiple biosimilar candidates toward approval. Supply chain resilience and operational efficiency remained a priority, and we continued optimizing our manufacturing footprint to support long-term reliability and profitability.

Focusing our business: We maintained disciplined capital allocation and ongoing efficiency initiatives. We continued to reduce debt, improving our balance sheet flexibility and resulting in increased credit ratings. In addition, Teva continued reallocating investment toward innovation while maintaining strong cost efficiencies. These efforts position Teva for continued operating margin expansion andlong-term, sustainable growth.

Growth Strategy Overseen by Highly Qualified Board

Your Board remains committed to effective oversight, with relevant expertise to oversee Teva’s growth and strategic transformation. Over the past five years, we have continued to strengthen the Board’s composition with the addition of four new directors, offering deep experience in biotechnology, global operations, finance, R&D, and risk management. Each of your Board’s members bring critical insights that support ourlong-term vision and reinforce our commitment to robust oversight and value creation for shareholders.

Supporting Our People and Building a Healthy Future

We are profoundly grateful for the resilience, dedication, and compassion of our people, particularly our colleagues and their families in Israel, who continue to navigate the

challenges of the ongoing conflict in the Middle East. The Board continues to prioritize oversight of our human capital management, talent development, and employee well-being programs to ensure we have the talent and cultural strength to support our strategic ambitions. Teva’s commitment to healthy people, a healthy planet, and a healthy business continues to guide our decisions.

Looking Ahead to 2026

Teva’s future is bright. In 2026, we expect: continued growth across our innovative portfolio, multiple clinical milestones for ourlate-stage assets, additional progress in our complex generics and biosimilars pipeline, further advancement of AI-enabled drug development, as well as ongoing operational discipline, debt reduction, and capital allocation optimization. This is not only a pivot to growth; it is the beginning of a wider transformation of Teva’s business andlong-term trajectory. Your continued support strengthens our commitment to innovation, excellence, and patient care. On behalf of the entire Board, thank you for your confidence in Teva and for sharing our vision for the company’s future.

Sincerely,

Dr. Sol J. Barer

Chairman of the Board of Directors

March 31, 2026